Intelligent nanobots offer the promise of smart drug delivery systems for a variety of therapeutic applications. A promise that experts in the field believe will become a reality within the next 30-40 years.
But at MedImmune, we don’t think patients should have to wait.
That’s why our researchers actively collaborate and investigate new efforts to explore possible applications of nanobots within our oncology, respiratory, and CVRM therapeutic areas.
This commitment has led to a deeper understanding of ways to leverage and deliver nanoparticles to various targets throughout the body to improve efficacy and lower overall toxicity, which has been demonstrated in in the recent edition of the Journal of Pharmaceutical Science.
Specifically, in preclinical models, our researchers were able to leverage their knowledge of nanotechnology to show that nanoparticles containing pyrrolobenzodiazepine (PBD) molecules can be used as an alternative to the widely used antibody drug conjugate approach. Their in vivo efficacy studies demonstrated that a single injection of nanoparticle PBD formulations could inhibit tumor growth for nearly three weeks, whereas the free drug failed to inhibit growth. What’s more, PBD-loaded nanoparticles did not lead to significant loss of body weight in the preclinical studies.
Anand Subramony, VP of Novel Product Technologies, shared that, “Nanotech offers the promise of smart delivery, which could potentially allow us to deliver medicines with traditionally high toxicity in a way that maximizes efficacy and limits toxicity for patients. The work we have accomplished in preclinical models this year has allowed us to take a significant step forward in our journey towards a potential nano-therapeutic application for patients.”
The next round of work is already underway, as the team explores new mechanisms and approaches that will further advance the field of nanotechnology.
Want to learn more about our latest work in nanotech? Check out our recent publications:
- Evaluation of Pyrrolobenzodiazepine-Loaded Nanoparticles: A Potential Targeted Drug Delivery Approach
- Ultrasmall targeted nanoparticles with engineered antibody fragments for imaging detection of HER2-overexpressing breast cancer
- Nanotherapeutics in oral and parenteral drug delivery: Key learnings and future outlooks as we think small